开云app官网登录入口网页版-官方正版

#EGFR突变阳性#

33篇内容 | 1060人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1785112, encodeId=67a01e8511223, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, objectType=article, longId=723968, objectId=3207e2396893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3207e2396893, replyNumber=0, likeNumber=81, createdTime=2022-06-18, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3207e2396893, moduleTitle=AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3207e2396893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785113, encodeId=bc3d1e85113cf, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=Lancet Respir Med：Furmonertinib一线治疗EGFR突变阳性NSCLC的效果明显优于吉非替尼！, objectType=article, longId=729047, objectId=d22fe2904783, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d22fe2904783, replyNumber=0, likeNumber=74, createdTime=2023-02-05, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d22fe2904783, moduleTitle=Lancet Respir Med：Furmonertinib一线治疗EGFR突变阳性NSCLC的效果明显优于吉非替尼！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d22fe2904783)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785111, encodeId=8f421e8511111, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=295658, objectId=04a8295658c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04a8295658c9, replyNumber=0, likeNumber=84, createdTime=2022-12-26, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04a8295658c9, moduleTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=04a8295658c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785106, encodeId=f34a1e85106f6, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=Lung Cancer：序贯阿法替尼和奥希替尼治疗EGFR突变阳性的NSCLC患者并获得T790M:一项全球非干预性研究(UpSwinG), objectType=article, longId=218470, objectId=7b082184e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b082184e0a7, replyNumber=0, likeNumber=60, createdTime=2022-06-25, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b082184e0a7, moduleTitle=Lung Cancer：序贯阿法替尼和奥希替尼治疗EGFR突变阳性的NSCLC患者并获得T790M:一项全球非干预性研究(UpSwinG), moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=7b082184e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785105, encodeId=ffe81e8510525, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, objectType=article, longId=214236, objectId=1c8821423607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8821423607, replyNumber=0, likeNumber=68, createdTime=2022-03-20, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8821423607, moduleTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1c8821423607)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785110, encodeId=24b51e85110ce, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=220889, objectId=d4ae2208892d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4ae2208892d, replyNumber=0, likeNumber=76, createdTime=2022-07-08, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4ae2208892d, moduleTitle=Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=d4ae2208892d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785109, encodeId=a21b1e851098d, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, objectType=article, longId=220865, objectId=1061220865c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1061220865c1, replyNumber=0, likeNumber=78, createdTime=2022-04-04, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1061220865c1, moduleTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1061220865c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785108, encodeId=75be1e8510860, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=A+T在EGFR突变阳性NSCLC的治疗新格局, objectType=article, longId=220696, objectId=2d11220696ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d11220696ee, replyNumber=0, likeNumber=53, createdTime=2022-06-25, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d11220696ee, moduleTitle=A+T在EGFR突变阳性NSCLC的治疗新格局, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2d11220696ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785107, encodeId=eaf31e85107a2, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗, objectType=article, longId=220083, objectId=ae6a2200837d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae6a2200837d, replyNumber=0, likeNumber=80, createdTime=2022-04-29, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae6a2200837d, moduleTitle=J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ae6a2200837d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785104, encodeId=833e1e851045f, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=J Thorac Oncol: 吉非替尼联合同步放疗治疗EGFR突变阳性的局部进展非小细胞肺癌（LA-NSCLC）患者的疗效和安全性：日本西部肿瘤组6911L, objectType=article, longId=213145, objectId=141f2131458b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=141f2131458b, replyNumber=0, likeNumber=69, createdTime=2021-10-08, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=141f2131458b, moduleTitle=J Thorac Oncol: 吉非替尼联合同步放疗治疗EGFR突变阳性的局部进展非小细胞肺癌（LA-NSCLC）患者的疗效和安全性：日本西部肿瘤组6911L, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=141f2131458b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785103, encodeId=d4d51e851035b, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=NEJM：奥希替尼作为EGFR突变阳性NSCLC术后辅助治疗，患者显著获益, objectType=article, longId=200981, objectId=96e62009817d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96e62009817d, replyNumber=0, likeNumber=62, createdTime=2021-01-17, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96e62009817d, moduleTitle=NEJM：奥希替尼作为EGFR突变阳性NSCLC术后辅助治疗，患者显著获益, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=96e62009817d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785097, encodeId=b1341e8509783, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=从规范性、可及性、安全性、疗效综合考虑，奥希替尼可谓EGFR突变阳性晚期NSCLC的一线治疗**, objectType=article, longId=183910, objectId=6dfe18391000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dfe18391000, replyNumber=0, likeNumber=92, createdTime=2020-09-05, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dfe18391000, moduleTitle=从规范性、可及性、安全性、疗效综合考虑，奥希替尼可谓EGFR突变阳性晚期NSCLC的一线治疗**, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6dfe18391000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785099, encodeId=f8a61e8509957, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=EGFR突变阳性晚期NSCLC一线治疗策略, objectType=article, longId=184327, objectId=4a2618432ef2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a2618432ef2, replyNumber=0, likeNumber=69, createdTime=2020-04-13, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a2618432ef2, moduleTitle=EGFR突变阳性晚期NSCLC一线治疗策略, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4a2618432ef2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785102, encodeId=93741e85102da, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, objectType=article, longId=193345, objectId=a58619334571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a58619334571, replyNumber=0, likeNumber=76, createdTime=2021-02-03, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a58619334571, moduleTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a58619334571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785100, encodeId=8fdc1e8510061, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局, objectType=article, longId=190904, objectId=3990190904f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3990190904f4, replyNumber=0, likeNumber=64, createdTime=2021-03-01, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3990190904f4, moduleTitle=林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3990190904f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785096, encodeId=c5a51e850966f, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=EGFR突变阳性晚期NSCLC的全程管理愈发重要, objectType=article, longId=182628, objectId=4294182628cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4294182628cc, replyNumber=0, likeNumber=68, createdTime=2020-05-07, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4294182628cc, moduleTitle=EGFR突变阳性晚期NSCLC的全程管理愈发重要, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4294182628cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785101, encodeId=f0141e8510166, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理, objectType=article, longId=192270, objectId=8c6d1922e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c6d1922e0a7, replyNumber=0, likeNumber=55, createdTime=2020-05-12, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c6d1922e0a7, moduleTitle=王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8c6d1922e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785098, encodeId=3cda1e8509822, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**, objectType=article, longId=183976, objectId=367f1839e6b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=367f1839e6b1, replyNumber=0, likeNumber=63, createdTime=2020-05-07, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367f1839e6b1, moduleTitle=长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=367f1839e6b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785094, encodeId=dc281e8509478, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=胡成平教授：EGFR突变阳性晚期NSCLC一线治疗方案选择, objectType=article, longId=168762, objectId=f104168e62dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f104168e62dd, replyNumber=0, likeNumber=61, createdTime=2020-04-20, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f104168e62dd, moduleTitle=胡成平教授：EGFR突变阳性晚期NSCLC一线治疗方案选择, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f104168e62dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785092, encodeId=f8a01e85092b9, content=<a href='/topic/show?id=0b4f65992c' target=_blank style='color:#2F92EE;'>#EGFR突变阳性#</a>, objectTitle=奥希替尼为EGFR突变阳性伴脑膜转移NSCLC患者带来显著获益, objectType=article, longId=164707, objectId=c304164e0717, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c304164e0717, replyNumber=0, likeNumber=67, createdTime=2019-12-22, rootId=0, userName=ms9833124466084992, userId=fc342500110, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c304164e0717, moduleTitle=奥希替尼为EGFR突变阳性伴脑膜转移NSCLC患者带来显著获益, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=c304164e0717)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

EGFR突变阳性

2020-05-29

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

AACR重磅之INSIGHT研究：特泊替尼+吉非替尼联合治疗显著改善了伴有MET扩增的EGFR突变阳性NSCLC患者无进展生存期和总生存期

2022-06-18

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

Lancet Respir Med：Furmonertinib一线治疗EGFR突变阳性NSCLC的效果明显优于吉非替尼！

2023-02-05

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效

2022-12-26

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

Lung Cancer：序贯阿法替尼和奥希替尼治疗EGFR突变阳性的NSCLC患者并获得T790M:一项全球非干预性研究(UpSwinG)

2022-06-25

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果

2022-03-20

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

Thorac Cancer：真实世界中dacomitinib（达可替尼）治疗伴有脑转移的EGFR突变阳性NSCLC患者的疗效

2022-07-08

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析

2022-04-04

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

A+T在EGFR突变阳性NSCLC的治疗新格局

2022-06-25

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

J Thorac Oncol：ADAURA研究：IB-IIIA期EGFR突变阳性NSCLC切除术后使用奥希替尼辅助治疗改善患者DFS，无论是否接受辅助化疗

2022-04-29

智慧医人 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

J Thorac Oncol: 吉非替尼联合同步放疗治疗EGFR突变阳性的局部进展非小细胞肺癌（LA-NSCLC）患者的疗效和安全性：日本西部肿瘤组6911L

2021-10-08

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

NEJM：奥希替尼作为EGFR突变阳性NSCLC术后辅助治疗，患者显著获益

2021-01-17

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

从规范性、可及性、安全性、疗效综合考虑，奥希替尼可谓EGFR突变阳性晚期NSCLC的一线治疗**

2020-09-05

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

EGFR突变阳性晚期NSCLC一线治疗策略

2020-04-13

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）

2021-02-03

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

林根教授：联合治疗协同增效，或将改写EGFR突变阳性晚期NSCLC的治疗格局

2021-03-01

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

EGFR突变阳性晚期NSCLC的全程管理愈发重要

2020-05-07

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

王燕教授：纵览EGFR突变阳性晚期NSCLC治疗，优化患者管理

2020-05-12

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**

2020-05-07

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

胡成平教授：EGFR突变阳性晚期NSCLC一线治疗方案选择

2020-04-20

ms9833124466084992 (审核中...)

前往app查看评论内容

#EGFR突变阳性#

奥希替尼为EGFR突变阳性伴脑膜转移NSCLC患者带来显著获益

2019-12-22

科室
- - 订阅+
  - 更多科室
工具
服务